合并胎儿心脏病变的抗SSA抗体阳性孕妇的临床及实验室特征

doi:10.19723/j.issn.1671-167X.2023.06.015

摘要/Abstract

摘要：

目的: 探究合并胎儿心脏病变的抗干燥综合征相关抗原A(Sjögren’s-syndrome-related antigen A, SSA)抗体阳性孕妇的临床表现、实验室指征及药物特征。方法: 在2013年1月至2023年7月于北京大学人民医院就诊且最终确诊自身免疫病的孕妇中, 选择抗SSA抗体阳性且超声确诊胎儿心脏病变的患者作为病变组, 抗SSA抗体阳性且超声检查无胎儿心脏病变的患者作为对照组, 收集两组患者的临床、实验室及用药信息, 比较组间基线数据无差异后对其临床指标进行统计学分析。结果: 合并胎儿心脏病变的抗SSA抗体阳性患者共11例, 其中有先天性房室传导阻滞表现者共7例, 是最常见的胎儿心脏病变类型。病变组患者孕前确诊自身免疫病的比例显著低于对照组(P=0.032), 多因胎儿心脏病变首次进行相关免疫学检查。病变组患者孕期白细胞水平[(9.29±2.58)×10⁹/L vs. (7.10±1.90)×10⁹/L, t=3.052, P=0.004]、红细胞沉降率[49.50(48.00, 51.00) mm/h vs. 23.00(15.00, 30.25) mm/h, Z=-2.251, P=0.024]、IgA水平[3.46(2.30, 5.06) g/L vs. 2.13(1.77, 2.77) g/L, Z=-2.181, P=0.029]、抗核抗体(antinuclear antibody, ANA)滴度[1∶320(1∶160, 1∶320) vs. 1∶80(1∶40, 1∶160), Z=-3.022, P=0.003]显著高于对照组。组间孕期合并SSB抗体阳性的比例(37.5% vs. 7.7%, P=0.053)、羟氯喹使用剂量及起用时间差异均无统计学意义。病变组孕期使用激素的比例及剂量显著高于对照组(P＜0.05), 其中孕早期两组间差异无统计学意义, 而孕中期、孕晚期病变组激素使用剂量显著高于对照组。结论: 胎儿心脏病变是一种罕见但与抗SSA抗体阳性高度相关的胎儿畸形, 孕期白细胞、红细胞沉降率、IgA水平及ANA滴度显著升高的患者胎儿心脏病变发生的风险更高。胎儿房室传导阻滞一旦发生便难以逆转, 因此, 预防和监测的重要性高于补救治疗。

关键词: 抗SSA抗体, 先天性心脏缺损, 心脏传导阻滞, 妊娠, 危险因素

Abstract:

Objective: To investigate the clinical manifestations and laboratory indicators of anti-Sjögren's-syndrome-related antigen A (SSA) antibody associated fetal cardiac disease. Methods: Pregnant women hospitalized at Peking University People's Hospital from January 2013 to July 2023 were included. Eleven patients with anti-SSA antibody positive were eventually diagnosed with fetal cardiac di-sease. And patients with anti-SSA antibody positive without fetal cardiac disease were selected as controls. Clinical manifestations, laboratory indications and drug usage were compared between the two groups. Results: Among these 11 patients, congenital heart block was confirmed in seven, which was the most common manifestations of fetal cardiac malformation. The proportion of the patients diagnosed with autoimmune disease before pregnancy in fetal cardiac malformation group was significantly lower than that in the control group (P=0.032), while most of the patients in the fetal cardiac malformation group received immune-related examinations for the first time because of this time's fetal cardiac diagnosis. While most of the patients in the control group received routine examinations because of autoimmune diseases diagnosed before pregnancy. During pregnancy, the white blood cell level [(9.29±2.58)×10⁹/L vs. (7.10±1.90×10⁹/L, t=3.052, P=0.004], erythrocyte sedimentation rate [(49.50 (48.00, 51.00) mm/h vs. 23.00 (15.00, 30.25) mm/h, Z=-2.251, P=0.024], IgA level [3.46 (2.30, 5.06) g/L vs. 2.13 (1.77, 2.77) g/L, Z=-2.181, P=0.029], and antinuclear antibody (ANA) titers [1∶320 (1∶160, 1∶320) vs. 1∶80 (1∶40, 1∶160), Z=-3.022, P=0.003] were significantly higher in fetal cardiac malformation group than in the control group. The proportion of positive anti-SSB antibody during pregnancy did not show a statistically significant difference between the two groups (37.5% vs. 7.7%, P=0.053). There was no significant difference in hydroxychloroquine dosage and initiation time between the two groups. The dosage of prednisone in the second and third trimesters was significantly higher in the cardiac malformation group than that in the control group, but there was no significant difference in the first trimester. Conclusion: Fetal cardiac disease is rare in pregnant women with anti-SSA antibody. White blood cell, erythrocyte sedimentation rate, IgA, the titer of ANA positivity were higher in the fetal heart disease group during pregnancy. Since congenital heart block is difficult to reverse, its prevention and monitoring are more important than remedial treatment.

Key words: Anti-Sjögren's-syndrome-related antigen A antibody, Congenital heart defects, Heart block, Pregnancy, Risk factors

中图分类号:

R593.2

李宇菲,闫亚妮,靳家扬,李春,裴秋艳. 合并胎儿心脏病变的抗SSA抗体阳性孕妇的临床及实验室特征[J]. 北京大学学报（医学版）, 2023, 55(6): 1053-1057.

Yu-fei LI,Ya-ni YAN,Jia-yang JIN,Chun LI,Qiu-yan PEI. Clinical characteristics of fetal cardiac disease in patients with anti-SSA antibody positive[J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1053-1057.

图/表 3

表1

表2

表3

参考文献 25

1	Yuan T , Shuo Y , Qi L , et al. Pregnancy-related complications in systemic lupus erythematosus[J]. J Autoimmun, 2022, 132, 102864. doi: 10.1016/j.jaut.2022.102864
2	Merz WM , Fischer-Betz R , Hellwig K , et al. Pregnancy and autoimmune disease[J]. Dtsch Arztebl Int, 2022, 119 (9): 145- 156.
3	Fausta B , Camilla B , Irene MD , et al. Impact of pregnancy on progression of preclinical autoimmune disorders: A prospective cohort study[J]. Rheumatology (Oxford), 2022, 62 (9): 2971- 2978.
4	Marder W , Littlejohn EA , Somers EC . Pregnancy and autoimmune connective tissue disease[J]. Best Pract Res Clin Rheumatol, 2016, 30 (1): 63- 80. doi: 10.1016/j.berh.2016.05.002
5	Fischer-Betz R , Specker C . Pregnancy in systemic lupus erythematosus and antiphospholipid syndrome[J]. Best Pract Res Clin Rheumatol, 2017, 31 (3): 397- 414. doi: 10.1016/j.berh.2017.09.011
6	李珊, 李明, 张旭. 19例新生儿红斑狼疮的心血管表现[J]. 广州医药, 2022, 53 (6): 48- 51.
7	Julkunen H , Eronen M . Long-term outcome of mothers of children with isolated heart block in Finland[J]. Arthritis Rheum, 2001, 44 (3): 647- 652. doi: 10.1002/1529-0131(200103)44:3<647::AID-ANR113>3.0.CO;2-I
8	Izmirly MP , Saxena A , Kim YM , et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus[J]. Circulation, 2011, 124 (18): 1927- 1935. doi: 10.1161/CIRCULATIONAHA.111.033894
9	Saxena A , Izmirly PM , Bomar RP , et al. Factors associated with long-term cardiac dysfunction in neonatal lupus[J]. Ann Rheum Dis, 2020, 79 (2): 217- 224. doi: 10.1136/annrheumdis-2019-215900
10	Habib SM , Vermeer MH . A baby with red plaques on the face and a first-degree heart block: Neonatal lupus[J]. Lancet, 2020, 396 (10260): 1432. doi: 10.1016/S0140-6736(20)32176-0
11	Wainwright B , Bhan R , Trad C , et al. Autoimmune-mediated congenital heart block[J]. Best Pract Res Clin Obstet Gynaecol, 2020, 64, 41- 51. doi: 10.1016/j.bpobgyn.2019.09.001
12	Brito-Zerón P , Izmirly PM , Ramos-Casals M , et al. The clinical spectrum of autoimmune congenital heart block[J]. Nat Rev Rheumatol, 2015, 11 (5): 301- 312. doi: 10.1038/nrrheum.2015.29
13	Aurélie A , Vijole D , Jeongsook P , et al. Anti-Ro52 monoclonal antibodies specific for amino acid 200-239, but not other Ro52 epitopes, induce congenital heart block in a rat model[J]. Ann Rheum Dis, 2012, 71 (3): 448- 454. doi: 10.1136/annrheumdis-2011-200414
14	Llanos C , Friedman DM , Saxena A , et al. Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus[J]. Rheumatology (Oxford), 2012, 51 (6): 1086- 1092. doi: 10.1093/rheumatology/ker515
15	Cuneo BF , Strasburger JF , Niksch A , et al. An expanded phenotype of maternal SSA/SSB antibody-associated fetal cardiac disease[J]. J Matern Fetal Neonatal Med, 2009, 22 (3): 233- 238. doi: 10.1080/14767050802488220
16	Tunks DR , Clowse EM , Miller GS , et al. Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents[J]. Am J Obstet Gynecol, 2013, 208 (1): 64.e1- 64.e7. doi: 10.1016/j.ajog.2012.09.020
17	Jaeggi E , Laskin C , Hamilton R , et al. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants[J]. J Am Coll Cardiol, 2010, 55 (24): 2778- 2784. doi: 10.1016/j.jacc.2010.02.042
18	Shinohara K , Miyagawa S , Fujita T , et al. Neonatal lupus erythematosus: Results of maternal corticosteroid therapy[J]. Obstet Gynecol, 1999, 93 (6): 952- 957.
19	刘蕾, 华益民, 周开宇. 新生儿狼疮综合征诊疗研究进展[J]. 中国循证儿科杂志, 2018, 13 (3): 231- 235.
20	Izmirly P , Kim M , Friedman MD , et al. Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of anti-SSA/Ro-positive mothers[J]. J Am Coll Cardiol, 2020, 76 (3): 292- 302. doi: 10.1016/j.jacc.2020.05.045
21	Julie B , Nathalie C , Adey B , et al. Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus[J]. Ann Rheum Dis, 2018, 77 (12): 1742- 1749. doi: 10.1136/annrheumdis-2018-213718
22	Strasburger FJ , Wacker-Gussmann A . Congenital heart block in subsequent pregnancies of SSA/Ro-positive mothers[J]. J Am Coll Cardiol, 2020, 76 (3): 303- 305. doi: 10.1016/j.jacc.2020.05.052
23	Friedman DM , Kim MY , Copel JA , et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: The PR Interval and Dexamethasone Evaluation (PRIDE) prospective study[J]. Circulation, 2008, 117 (4): 485- 493.
24	Gleicher N , Elkayam U . Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: A review of published literature and registered clinical trials[J]. Autoimmun Rev, 2013, 12 (11): 1039- 1045.
25	张利, 米荣, 王晓颖, 等. 静脉注射人免疫球蛋白治疗45例新生儿红斑狼疮的疗效[J]. 中国新药与临床杂志, 2023, 42 (6): 378- 382.

相关文章 15

[1]	罗靓,李云,王红彦,相晓红,赵静,孙峰,张晓盈,贾汝琳,李春. 抗内皮细胞抗体检测在早期流产中的预测价值[J]. 北京大学学报（医学版）, 2023, 55(6): 1039-1044.
[2]	吴洁,张雯,梁舒,秦艺璐,范文强. 妊娠期原发性干燥综合征合并视神经脊髓炎谱系疾病危重症1例[J]. 北京大学学报（医学版）, 2023, 55(6): 1118-1124.
[3]	游芳凝,罗靓,刘香君,张学武,李春. 未分化结缔组织病患者的妊娠结局、疾病演变及其影响因素[J]. 北京大学学报（医学版）, 2023, 55(6): 1045-1052.
[4]	徐金辉,韩娜,苏涛,林力孜,计岳龙,周双,包鹤龄,刘峥,罗树生,徐相蓉,王海俊. 孕早期单纯甲状腺过氧化物酶抗体阳性与胎儿生长的关联[J]. 北京大学学报（医学版）, 2023, 55(5): 886-892.
[5]	魏慧,次旦央宗,益西拉姆,白玛央金. 高原地区不同类型过敏性紫癜藏族患者发病的相关危险因素[J]. 北京大学学报（医学版）, 2023, 55(5): 923-928.
[6]	林咏惟,周雅琳,赵润茏,许雅君,刘燕萍. 孕早期女性铁营养状况及其影响因素分析[J]. 北京大学学报（医学版）, 2023, 55(4): 600-605.
[7]	朱薇,祝斌,刘晓光. 全内镜下突出腰椎间盘摘除术后功能状态的影响因素[J]. 北京大学学报（医学版）, 2023, 55(3): 537-542.
[8]	孙希雅,陈艺璐,曾琳,闫丽盈,乔杰,李蓉,智旭. 不孕女性维生素D水平与抗苗勒氏管激素的相关性及对妊娠结局的预测[J]. 北京大学学报（医学版）, 2023, 55(1): 167-173.
[9]	罗靓,蔡青猛,刘香君,贠泽霖,李春,张晓盈. 以雷诺现象为首发表现的系统性硬化症临床特征及其相关因素[J]. 北京大学学报（医学版）, 2022, 54(6): 1224-1228.
[10]	森本智惠子,王益勤,周蓉,王建六. 子宫内膜非典型增生及子宫内膜癌患者保留生育功能治疗的临床研究[J]. 北京大学学报（医学版）, 2022, 54(5): 936-942.
[11]	张红霞,杨蕊,杨硕,潘宁宁,王琳琳,李蓉. 经腹胎儿颅内与胸腔内注射氯化钾减胎的临床效果[J]. 北京大学学报（医学版）, 2022, 54(5): 943-947.
[12]	梁喆,范芳芳,张岩,秦献辉,李建平,霍勇. 中国高血压人群中H型高血压的比率和特征及与美国人群的比较[J]. 北京大学学报（医学版）, 2022, 54(5): 1028-1037.
[13]	陈阳阳,周玉博,杨静,花语蒙,原鹏波,刘爱萍,魏瑗. 双胎妊娠孕期体质量对血清高敏C反应蛋白与妊娠期糖尿病关联的影响：一项队列研究[J]. 北京大学学报（医学版）, 2022, 54(3): 427-433.
[14]	钱婧,魏友加,程毅菁,张奕,彭博,朱春梅. 儿童坏死性肺炎临床特征及危险因素分析[J]. 北京大学学报（医学版）, 2022, 54(3): 541-547.
[15]	于博,赵扬玉,张喆,王永清. 妊娠合并感染性心内膜炎1例[J]. 北京大学学报（医学版）, 2022, 54(3): 578-580.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Parameters	Cardiac malformation (n=11)	Control (n=44)	P
Clinical feature, n(%)
History of miscarriage	5 (45.5)	22 (50.0)	> 0.999
Leukopenia during pregnancy	0	7 (15.9)	0.323
Thrombocytopenia during pregnancy	2 (18.2)	10 (22.7)	> 0.999
Diagnosis of autoimmune disease before pregnancy	6 (54.5)	38 (86.4)	0.032
Complicating disease, n(%)
Hashimoto thyroiditis	2 (18.2)	2 (4.5)	0.175
Hyperthyroidism	0	0	> 0.999
Hypothyroidism	1 (9.1)	8 (18.2)	0.669
Gestational diabetes mellitus	1 (9.1)	3 (6.8)	> 0.999
Ovarian tumor	0	2 (4.5)	> 0.999

Parameters	Cardiac malformation (n=11)	Control (n=44)	Z/t/χ²	P
WBC during pregnancy/(×10⁹/L)	9.29±2.58	7.10±1.90	3.052	0.004
PLT during pregnancy/(×10⁹/L)	202.20±79.05	171.51±56.68	1.428	0.159
ESR during pregnancy/(mm/h)	49.50 (48.00, 51.00)	23.00 (15.00, 30.25)	-2.251	0.024
IgA during pregnancy/(g/L)	3.46 (2.30, 5.06)	2.13 (1.77, 2.77)	-2.181	0.029
ANA positive during pregnancy	10/10 (100.0)	38/40 (95.0)		> 0.999
ANA titer during pregnancy	1∶320 (1∶160, 1∶320)	1∶80 (1∶40, 1∶160)	-3.022	0.003
Anti-SSB positive during pregnancy	3/8 (37.5)	3/39 (7.7)		0.053

Parameters	Cardiac malformation (n=11)	Control (n=44)	Z/t/χ²	P
HCQ
Use of HCQ during pregnancy, n(%)	10 (90.9)	35 (79.5)		0.667
Use of HCQ during the first trimester, n(%)	6 (54.5)	33 (75.0)		0.266
HCQ dose in the first trimester/mg, M (P₂₅, P₇₅)	200 (0, 200)	200 (25, 200)	-1.117	0.264
HCQ dose in the second trimester/mg, M (P₂₅, P₇₅)	200 (200, 200)	200 (100, 200)	-0.555	0.579
HCQ dose in the third trimester/mg, M (P₂₅, P₇₅)	200 (200, 200)	200 (125, 200)	-1.098	0.272
Prednisone
Use of prednisone during pregnancy, n(%)	9 (81.8)	16 (36.4)		0.015
Prednisone dose in the first trimester/mg, M (P₂₅, P₇₅)	0 (0, 10.00)	0 (0, 5.00)	-0.593	0.553
Prednisone dose in the second trimester/mg, M (P₂₅, P₇₅)	10.00 (0, 20.00)	0 (0, 5.00)	-2.924	0.003
Prednisone dose in the third trimester/mg, M (P₂₅, P₇₅)	10.00 (5.00, 26.70)	0 (0, 5.00)	-3.347	0.001